Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Predictive Biomarkers for Efficacy of Cytarabine in Acute Myeloid Leukemia Therapeutics
FY 2022-23
Summary
Acute Myeloid Leukemia (AML) is a highly heterogeneous and aggressive type of blood cancer affecting approximately 1,300 Canadians yearly. The front-line chemotherapy drug that is commonly administered to AML patients is cytarabine. However, cytarabine treatment is not effective in all patients. Some patients benefit from this chemotherapy while others don't, and we still don't understand why. Therefore, there is a need to increase the effectiveness of cytarabine for all patients. For a long time, it has been thought that cytarabine kills AML cells by binding to and blocking production of DNA, the genetic instruction code that keeps cells alive, and causing apoptosis, one type of very controlled death mechanism. However, recent work from our lab shows that cytarabine may have a different target than DNA and that other types of cell death mechanisms may be involved. Therefore, the main goal of this project is to understand the type of death cytarabine induces in AML and develop tools to identify treatment response biomarkers which are measurable indicators of whether treatment with cytarabine will be effective in patients. Furthermore, if we can understand why this drug is effective in some patients and not effective in others, we can target it therapeutically and develop better treatment options for each patient.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475822
Name
Maru Bruktawit
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Predictive Biomarkers for Efficacy of Cytarabine in Acute Myeloid Leukemia Therapeutics
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukaemia; Cytarabine Anabolism; Drug Sensitivity Modulation; Nucleic Acid Therapy; Parp1; Predictive Biomarkers; Rna Activation; Therapeutic Oligonucleotides
Abstract
Acute Myeloid Leukemia (AML) is a highly heterogeneous and aggressive type of blood cancer affecting approximately 1,300 Canadians yearly. The front-line chemotherapy drug that is commonly administered to AML patients is cytarabine. However, cytarabine treatment is not effective in all patients. Some patients benefit from this chemotherapy while others don't, and we still don't understand why. Therefore, there is a need to increase the effectiveness of cytarabine for all patients. For a long time, it has been thought that cytarabine kills AML cells by binding to and blocking production of DNA, the genetic instruction code that keeps cells alive, and causing apoptosis, one type of very controlled death mechanism. However, recent work from our lab shows that cytarabine may have a different target than DNA and that other types of cell death mechanisms may be involved. Therefore, the main goal of this project is to understand the type of death cytarabine induces in AML and develop tools to identify treatment response biomarkers which are measurable indicators of whether treatment with cytarabine will be effective in patients. Furthermore, if we can understand why this drug is effective in some patients and not effective in others, we can target it therapeutically and develop better treatment options for each patient.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maru, Bruktawit
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~